Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Pabst Gabriel |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2023
Originalarbeit (Zeitschrift)
** Foßelteder, J; Pabst, G; Sconocchia, T; Schlacher, A; Auinger, L; Kashofer, K; Beham-Schmid, C; Trajanoski, S; Waskow, C; Schöll, W; Sill, H; Zebisch, A; Wölfler, A; Thomas, D; Reinisch, A
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
Leukemia. 2023; 37(4): 843-853.
Doi: 10.1038/s41375-023-01848-6
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S
Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189.
[Poster]
Web of Science
FullText
2021
Originalarbeit (Zeitschrift)
** Jensen, TI; Mikkelsen, NS; Gao, Z; Foßelteder, J; Pabst, G; Axelgaard, E; Laustsen, A; König, S; Reinisch, A; Bak, RO
Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi.
Genome Res. 2021; 31(11):2120-2130
Doi: 10.1101/gr.275607.121
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Foßelteder, J; Schlacher, A; Pabst, G; Amtmann, B; Schöll, W; Kashofer, K; Beham-Schmid, C; Schlenke, P; Greinix, HT; Sill, H; Woelfler, A; Zebisch, A; Reinisch, A
Introduction and Genetic Correction of Calreticulin Mutations in Human Hematopoietic Stem and Progenitor Cells Sheds Light on MPN Pathogenesis
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-147919
[Poster]
Web of Science
FullText
FullText_MUG
** Pabst, G; Foßelteder, J; Schlacher, A; Auinger, L; Martinez-Krams3, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, C; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-149591
[Poster]
Web of Science
FullText
FullText_MUG
2020
Kurzbericht/Letter
** Pabst, G; Lind, K; Graf, R; Zebisch, A; Stölzel, F; Döhner, K; Heitzer, E; Reinisch, A; Sill, H
TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model.
Ann Hematol. 2020; 99(3):653-655
Doi: 10.1007/s00277-020-03920-y
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Originalarbeit (Zeitschrift)
** Prochazka, KT; Pregartner, G; Rücker, FG; Heitzer, E; Pabst, G; Wölfler, A; Zebisch, A; Berghold, A; Döhner, K; Sill, H
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.
Haematologica. 2019; 104(3):516-523
Doi: 10.3324/haematol.2018.205013
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Abstract (Zeitschrift)
** Pabst, G; Prochazka, K; Pregartner, G; Rücker, FG; Heitzer, E; Woelfler ,A; Zebisch, A; Berghold, A; Döhner, K; Sill H.
Impact of TP53 mutated subclones in acute myeloid leukemia
Blood. 2018; 132(Suppl ):-Annual Meeting of the American Society of Hematology; December 1-4, 2018; San Diego.
Doi: 10.1182/blood-2018-99-110667
[Poster]
Web of Science
FullText
FullText_MUG